title: Tumor idiotype vaccines. VI. Synergistic anti-tumor effects with combined "internal image" anti-idiotypes and chemotherapy.
abstract: Anti-Id antibodies that have biologic activity as stimulators of specific immunity have been used in experimental vaccines and tumor protection models. However, very little is known about the therapeutic potential of anti-Id antibodies in animals and men. In this study we explored the combination of anti-Id and chemotherapy in a murine tumor system for which we had previously generated protective anti-Id mAb. First, we investigated various protocols by using a protective anti-Id in active immunization. Mice preimmunized before tumor transfer and challenged again after tumor survived significantly longer. Next, we explored the use of soluble anti-Id as immunostimulator in tumor-bearing mice. Although this treatment did not induce long-term survival, it significantly increased survival time. Interestingly, this anti-Id effect was dose dependent, whereby large and small doses had no effect. Finally, stimulatory anti-Id therapy and cyclophosphamide (Cy) treatment was combined. Tumor bearing mice were given a single dose of Cy followed by different doses of soluble anti-Id. The optimal effect on tumor growth and survival was achieved with 80 mg/kg Cy and 10 micrograms/mouse of anti-Id, where 80% of mice survived longer than 100 days. These results provide guidelines for developing clinical protocols for cancer patients by using combination therapy of anti-Id and chemotherapy.
authors.affiliation: Department of Microbiology, State University of New York, Buffalo 14214.
authors.forename: J J
authors.initials: JJ
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Saeki
authors.forename: L F
authors.initials: LF
authors.lastname: Shi
authors.forename: H
authors.initials: H
authors.lastname: Köhler
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004306:Dose-Response Relationship, Immunologic; D006433:Hemocyanins / Q000276:immunology; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D007939:Leukemia L1210 / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D051379:Mice; D008805:Mice, Inbred A; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007130:Immunoglobulin Idiotypes; D003520:Cyclophosphamide; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin